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Summary 
 
The proto-oncoprotein Myc is known to promote glutamine usage by up-regulating 
glutaminase (GLS), which converts glutamine to glutamate that is catabolized in the 
tricarboxylic acid (TCA) cycle.  Here we report that in a number of human and murine 
cells and cancers, Myc overexpression leads to elevated expression of glutamate-
ammonia ligase (GLUL), also termed glutamine synthetase (GS), which catalyzes the de 
novo synthesis of glutamine from glutamate and ammonia.  Elevated expression of GS 
promotes cell survival under glutamine limitation, while silencing of GS leads to 
decreased cell proliferation and xenograft tumor growth.  Stable isotope based 
metabolite tracing shows that GS overexpression increases glutamine synthesis, 
cataplerotic flux at the -ketoglutarate (KG) step of the TCA cycle, and contributes to 
nucleotide synthesis and amino acid transport.  Mechanistically, Myc binds to the 
promoter of thymine DNA glycosylase (TDG) and upregulates its expression, which 
leads to active demethylation of the GS promoter and its increased expression.  These 
results demonstrate an unexpected role of Myc in promoting glutamine synthesis, and 
suggest a previously uncovered molecular connection between DNA demethylation and 
glutamine metabolism in Myc-driven cancers. 
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Introduction 
Cancer cells rewire their metabolic programs to benefit their growth, proliferation, and 
survival (DeBerardinis et al., 2008).  Abnormal glutamine metabolism is a defining 
hallmark of metabolic reprogramming.  Some cancer cell lines display increased 
glutamine uptake and catabolism that render cells addicted to glutamine, which plays a 
critical role in malignant transformation by contributing to energy production by fueling 
the TCA cycle.  Nonetheless, in addition to being a nutrient substrate, glutamine is 
involved in other biological processes including serving as the obligate nitrogen donor for 
the synthesis of nucleotides and non-essential amino acids, as an exchanger for the import 
of essential amino acids, and as a means to detoxifying intracellular ammonia and 
glutamate (Dang, 2012; DeBerardinis and Cheng, 2010; Hensley et al., 2013; Wise and 
Thompson, 2010) 
 
While the metabolic changes in cancer cells can be promoted by a passive cell adaptation 
to environmental conditions such as hypoxia and redox stress, they are often actively 
regulated by genetic alterations such as activation of oncoproteins and loss of tumor 
suppressors (DeBerardinis et al., 2008; Kroemer and Pouyssegur, 2008; Vander Heiden et 
al., 2009).  Two proto-oncoproteins, Akt and c-Myc (hereafter referred to as Myc), have 
been intensively studied for their functions in regulating cell metabolism.  Both Akt and 
Myc can promote aerobic glycolysis, also termed the Warburg effect.  With regard to 
glutamine metabolism the specific role of Akt is not yet well understood, but oncogenic 
Myc has been shown to promote glutamine uptake by directly transactivating the 
expression of glutamine transporters SLC1A5 and SLC7A5/SLC3A2 (Nicklin et al., 
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2009), and to promote glutaminolysis by increasing the expression of glutaminase (GLS) 
via transcriptional suppression of the GLS repressor micro RNAs (miR)-23a/b (Gao et 
al., 2009).  In a previous study (Fan et al., 2010), we established an isogenic dual-
regulatable FL5.12 pre-B cell line in which myrAkt is expressed under the control of 
doxycycline (DOX), and Myc, fused to the hormone-binding domain of the human 
estrogen receptor (ER), is activated by 4-hydroxytamoxifen (4-OHT).  Using this 
system, we have shown that Akt and Myc have differential effects on mitochondrial 
function which render cancer cells susceptible to the perturbation of different metabolic 
programs (Fan et al., 2010).  We continued our study to compare their effects on gene 
expression using the Affymetrix DNA array analysis.  To our surprise, we found that 
Myc but not Akt can upregulate the expression of glutamine synthetase (GS), the enzyme 
that catalyzes the synthesis of glutamine from glutamate and ammonia, which is the 
reverse reaction of glutaminolysis that is catalyzed by GLS.  Here we studied Myc-
mediated upregulation of GS and its biological relevance. 
 
Results 
 
Myc upregulates GS expression and activity  
To compare the transcriptional regulation controlled by Akt and Myc, we used the 
FL5.12 Akt/Myc (AM) clones that we previously established where myrAkt and Myc can 
be induced individually or simultaneously in an isogenic background (Fan et al., 2010).  
An Affymetrix mouse cDNA array showed that GS expression was increased upon Myc 
but not Akt activation (Fig. 1A).  This induction of GS expression was confirmed in two 
individual clones (AM10 and AM32) at both the transcription (Fig. 1B) and protein levels 
Bott et al.  Page 5 
 
(Fig. 1C).  The increased GS expression was accompanied by an increased GS 
enzymatic activity (Fig. 1D), using the GS activity assay whose specificity was validated 
using the GS-specific inhibitor methionine sulfoximine (MSO) and two independent GS 
shRNAs (Fig. 1E and 1F).  Under a physiological setting, introduction of Myc into the 
Pdx1-Cre; LSL-KRasG12D model (Hingorani et al., 2003) by breeding it to the Rosa26-
LSL-Myc mice (Murphy et al., 2008) led to a massive increase of GS expression in the 
pancreatic ductal neoplasia compared with the age-matched control KRasG12D mice 
(Fig. 1G).  In the lung tumor cells isolated from the LSL-KRasG12D; tp53flox/flox mice 
(Jackson et al., 2001), induction of Myc using the MycER system also led to elevated GS 
mRNA level as seen by RNA-sequencing (RNA-Seq) analysis (Fig. 1H).  In the 
immortalized yet non-transformed human mammary epithelial cell line MCF10A, 
expression of Myc (Fig. 1I), which stimulated cell proliferation (Fig. 1J), also led to 
elevated GS expression at both protein (Fig. 1I) and transcript levels (Fig. 1K) that 
corresponded with increased enzymatic activity (Fig. 1L).  It is interesting to note that 
GLS protein level did not increase in this system (Fig. 1I).  Using the Cancer Genome 
Atlas (TCGA) data of human T-lymphoma with Myc amplification and with sizable 
samples, a strong correlation between Myc amplification and GS expression was 
observed (Fig. 1M).  Conversely, in a number of human cancer cell lines, silencing of 
endogenous Myc led to decreased GS expression, yet variable changes in the GLS level 
(Fig. 1N).  These data indicate that Myc upregulation can promote GS expression in 
numerous mouse and human cell lines and cancers.   
 
Myc directly upregulates TDG that leads to GS expression via promoter 
demethylation 
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We next studied how Myc induces GS expression.  As Myc amplification is a major 
oncogenic event in human breast cancer, we focused on human breast epithelial cell lines 
for the following studies.  Five out of the 6 breast cancer cell lines that we examined 
showed strong GS expression, excluding Hs578T cells (Fig. 2A).  Therefore, we utilized 
Hs578T cells for studying the effect of GS upregulation in cancerous cells.  We also 
chose to use MCF10A cells which have low levels of GS expression (Fig. 1G) to study 
GS regulation upon Myc activation in non-transformed cells.  Myc is a helix-loop-helix 
leucine zipper family transcriptional regulator that dimerizes with Max family proteins to 
bind the CAC(G/A)TG (E-box) sequence and directly activates transcription of its target 
genes.  However, analysis of the putative GS promoter regions using the Genomatix 
Genome Analyzer (http://www.genomatix.de) and the SABiosciences Transcription 
Factor Search Portal (http://www.sabiosciences.com) showed no canonical Myc binding 
sites in human, mouse, or rat GS promoters, consistent with previous analysis of the GS 
promoter (Kung et al., 2011).  Interestingly, we noticed G/C rich regions spanning the 
transcriptional starting site in the GS gene, which was predicted to be a CpG island by the 
CpG Island Searcher (http://www.cpgislands.com) (Fig. 2B).  This suggested a possible 
mechanism of transcriptional regulation by DNA methylation of the GS promoter.  
Indeed, treatment with 5-azacytidine, a DNA methyltransferase inhibitor, enhanced GS 
expression in both MCF10A and Hs578T cells (Fig. 2C).  Bisulfite sequencing showed 
that the GS promoter was indeed methylated and that Myc expression led to its decreased 
methylation (Fig. 2D).  To determine how Myc affects GS promoter methylation, we 
examined the expression of the major DNA methyltransferases and demethylases upon 
Myc expression.  While Myc did not cause significant changes in the expression level of 
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DNA methyltransferases DNMT1, DNMT3A, and DNMT3B, or that of the DNA 
demethylases TET1, TET2, and MBD4 (Suppl. Fig. S1A), it induced a significant 
increase in the expression of TET3 (Suppl. Fig. S1A) and TDG (Fig. 2E).  This suggests 
that Myc can induce “active demethylation” by up-regulating TET3 which oxidizes 5-
methylcytosine (5mC) and TDG which then removes the oxidized products via excision 
repair (He et al., 2011; Ito et al., 2011).  Supporting the active demethylation theory, 
increased DNA demethylase activity was observed in Myc-expressing cells (Fig. 2F).  
Gemcitabine, a pharmacological inhibitor of DNA demethylation, suppressed Myc-
induced GS expression in both MCF10A-Myc (Fig. 2G) and in FL5.12-AM32 cells 
(Suppl. Fig. S1B).   
 
We further characterized how Myc induces TET3 and TDG expression.  Interestingly, 
two recent independent genome-wide chromatin immunoprecipitation-sequencing (ChIP-
Seq) analyses suggested that Myc can directly bind to the promoter of TDG but not of 
TET3 (Perna et al., 2012; Walz et al., 2014).  Promoter analysis identified two putative 
E-boxes in TDG promoter.  We then focused on exploring TDG as a direct Myc target.  
ChIP analysis was performed in the Myc-expressing MCF10A cells using an anti-Myc 
antibody.  PCR analysis using two specific sequences containing the E-boxes revealed 
that Myc was recruited to the TDG promoter (Fig. 2H).  We then generated luciferase 
reporter constructs driven by wild-type TDG promoter or promoters mutated at E-box 
consensus sites.  While the wild-type promoter drove a significantly higher luciferase 
activity in Myc-expressing cells, both single E-box mutants and the double mutant lost 
the Myc-mediated inducibility (Fig. 2I).  Using the FL5.12-MycER cells and MCF10A-
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MycER cells where Myc can be acutely induced, we observed a rapid induction of GS 
and TDG as early as 4 h and 8 h respectively upon Myc activation (Fig. 2J and Suppl. 
Fig. S1C), which correlated with decreased GS promoter methylation (Suppl. Fig. S1D 
and S1E) and is consistent with the active demethylation mechanism which is replication-
independent.  Lastly, TDG silencing in Myc-expressing MCF10A cells abrogated Myc-
induced GS expression (Fig. 2K).  Therefore, we identified a previously undescribed 
mechanism whereby Myc activates GS expression via the demethylation of its promoter.   
 
Myc-induced GS promotes glutamine metabolism 
We then studied the effect of GS in cancer cells.  GS was ectopically expressed in 
Hs578T cells which have low endogenous levels of GS (Fig. 3A).  GS catalyzes the 
condensation of glutamate and ammonia into glutamine.  Therefore, cells were 
incubated with 15N-labeled ammonia (NH4Cl) and subjected to gas chromatography-mass 
spectrometry (GC-MS) analysis.  In vector control cells ~ 30% of the intracellular 
glutamine was m+1 (15N1) labeled, which is produced by the condensation of m+0 
glutamate and NH4Cl.  The expression of GS led to a significant increase in 
15N 
incorporation into glutamine with over 40% of the glutamine m+1 labeled (Fig. 3B), 
demonstrating that GS overexpression promotes glutamine synthesis.   
 
Myc is known to promote glutaminolysis which leads to increased anaplerosis at the 
KG step of the TCA cycle (DeBerardinis et al., 2007; Wise et al., 2008).  Hence GS-
promoted glutamine synthesis might be expected to consume TCA cycle intermediates, of 
which a major source is glucose.  Therefore, 13C-glucose was traced in GS-expressing 
Hs578T cells.  Consistent with the 15N-NH4Cl labeling, tracing of the 
13C-labeled 
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glucose showed increased glutamine in GS-expressing Hs578T cells (Fig. 3C), 
accompanied by a reduced relative abundance of glutamate (Fig. 3D) and KG (Fig. 3E).  
We did not observe significant changes in 13C incorporation into pyruvate and lactate, 
two of the glycolytic metabolites most proximal to the TCA cycle (Fig. 3F), nor did we 
observe a significant difference in the TCA cycle intermediate citrate (Fig. 3F).  
Moreover, the abundance of succinate, fumarate, and malate were significantly reduced 
(Fig. 3F).  These data suggest that enforced expression of GS promotes cataplerotic 
efflux of the TCA cycle from the point of KG.   
 
Based on these data we sought to determine the fate of newly synthesized glutamine in 
both the context of GS and Myc overexpression.  Aside from the anapleurotic role of 
glutamine in contributing carbons to the TCA, glutamine plays a major role in a variety 
of cellular anabolic processes.  This contribution is predominately via the donation of 
the terminal nitrogen group which can be assayed via 15N-NH4Cl labeling which can be 
monitored by both GC-MS and LC-MS.  To directly determine the fate of glutamine, we 
utilized the 15N-NH4Cl labeling followed by methanol extraction of metabolites then 
tracing via liquid chromatography-mass spectrometry (LC-MS).  Consistent with the 
GC-MS data (Fig. 3B), LC-MS also revealed significant incorporation of 15N into 
glutamine accompanied by increased asparagine, the recipient of the terminal 15N-amine 
group donated by glutamine (Fig. 3G).  Interestingly, labeling patterns revealed that 
while the incorporation of 15N into glutathione, which is synthesized from glutamate, was 
reduced, the 15N incorporation into ribonucleosides and monophosphate nucleotides was 
markedly increased in GS-expressing cells (Fig. 3G).   
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Importantly, similar to the GS-overexpressing cells (Fig. 3B), an increase in the fraction 
of m+1 (15N1) glutamine was observed in Myc-expressing MCF10A cells by GC-MS 
using the 15N-NH4Cl labeling (Fig. 3H).  As GS promoted nucleotide synthesis (Fig. 
3G) and Myc stimulated MCF10A cell proliferation (Fig. 1J), we examined whether GS 
plays a role in Myc-induced nucleotide synthesis, which would correlate with increased 
DNA synthesis and cell proliferation.  To this end, GS was silenced in Myc-expressing 
MCF10A cells (Fig. 3I), and the cells were subjected to 15N-NH4Cl labeling followed by 
LC-MS.  Similar to the result obtained by GC-MS (Fig. 3H), Myc activation led to 
increased 15N-glutamine and 15N-asparagine, which was markedly reduced upon GS 
silencing (Fig. 3J).  The 15N incorporation into glutathione, NADH, and N-acetyl-
glucosamine-6-phosphate was not drastically affected upon GS silencing, suggesting GS-
independent regulation mechanisms for these metabolites in Myc-active cells (Fig. 3J).  
Importantly, in Myc-overexpressing cells, although they did not show drastically 
increased steady-state levels of methanol-soluble free ribonucleosides, likely due to the 
faster incorporation of free nucleotides into DNA or RNA strands as indicated by faster 
proliferation of the Myc cells, GS silencing led to a marked decrease of the steady-state 
level of 15N incorporation into ribonucleosides (Fig. 3J).  Together, these results 
strongly indicate that GS promotes glutamine production which can be used for anabolic 
processes such as synthesis of asparagine and nucleotides in Myc active cells. 
 
GS promotes amino acid transport, cell survival, and oncogenesis 
To assay another downstream function of this glutamine anabolic program, we also tested 
Bott et al.  Page 11 
 
the possibility of glutamine acting as an exchange factor in the bidirectional transport of 
leucine (Nicklin et al., 2009).  Overexpression of GS alone was sufficient to increase 
leucine uptake by approximately 20%, in a System L-dependent manner as the uptake 
was abrogated by the System L inhibitor BCH (Fig. 4A, left and right panels).  The 
importance of intracellular amino acids for system L-mediated leucine uptake in both cell 
lines was also demonstrated by the inhibition of leucine uptake when cells were 
incubated in amino acid depleted media (Fig 4A, KRB).  Additionally, high level of GS 
provided a sustained ability to uptake leucine even in the absence of extracellular 
glutamine (Fig. 4A), in agreement with GS contributing to increased intracellular levels 
of glutamine that act as an efflux substrate for the uptake of leucine (Krokowski et al., 
2013; Nicklin et al., 2009).  Consistent with the increased leucine uptake and glutamine 
efflux, increased levels of extracellular glutamine was detected in GS-expressing cells 
(Fig. 4B).     
 
We then went on to determine the biological consequences of GS expression.  In 
Hs578T cells, overexpression of GS enhanced cell viability upon glutamine deprivation 
(Fig. 4C and 4D).  Conversely, silencing GS in Myc-expressing MCF10A cells led to 
decreased cell proliferation in complete medium (Fig. 4E) and sensitized cells to 
glutamine deprivation (Fig. 4F).  The generality of this phenomenon was further 
illustrated by silencing GS with two independent shRNAs in MCF10A-Myc and the more 
aggressive breast cancer cell lines MDA-MB-231 and MDA-MB-468 (Fig. 4G), which 
led to decreased proliferation (Fig. 4H).  Silencing of GS did not have an obvious effect 
on the non-transformed MCF10A parental cells (Fig. 4G and 4H).  GS silencing also led 
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to spontaneous cell death in MDA-MB-231 cells (Fig. 4I).  The pro-survival role of GS 
was further demonstrated using the GS inhibitor MSO that enhanced cell sensitivity to 
glutamine deprivation in Myc-expressing cells (Fig. 4J).  Interestingly, unlike MSO, 
BPTES, the inhibitor of GLS, did not confer sensitivity to glutamine deprivation but 
rather suppressed cell death in the MCF10A-Myc cells (Fig. 4K and 4L), consistent with 
an anabolism-promoting function of glutamine.  Furthermore, to test the effect of GS 
suppression in vivo, we introduced a Tet-inducible GS shRNA in MDA-MB-468 cells 
that have high level of endogenous GS.  Addition of doxycycline led to a progressive 
loss of GS (Fig. 5A) as well as decreased cell growth (Fig. 5B) and xenograft tumor 
growth (Fig. 5C).  These data indicate that GS promotes cell proliferation and survival, 
and may be a viable therapeutic target in Myc-driven cancers. 
 
Discussion 
Here we report that Myc upregulates expression of GS, the enzyme that catalyzes the 
formation of glutamine from glutamate and ammonia.  This Myc-induced GS expression 
promotes glutamine anabolism and is associated with cell proliferation, survival, and 
xenograft tumor growth, suggesting an important role of GS in Myc-driven cancers.  In 
addition to being a nutrient substrate, glutamine is involved in many important biological 
processes including serving as the obligate nitrogen donor for multiple steps in both 
purine and pyrimidine synthesis and can contribute to the production of non-essential 
amino acids (DeBerardinis and Cheng, 2010; Wise and Thompson, 2010).  A recent 
report showed that cell death induced by glutamine deprivation is not mediated by 
lowered TCA cycle intermediates, but rather through a mechanism dependent on 
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asparagine, which is produced by aspartate receiving nitrogen from glutamine (Zhang et 
al., 2014).  Indeed, our data indicate that several fates elucidated for newly synthesized 
glutamine, namely nucleotide and asparagine synthesis as well as amino acid transport 
(Fig. 3F and 4A), fit into the anabolism-promoting role of glutamine.   
 
The connection between Myc and numerous essential cellular processes (macromolecule 
biosynthesis, ribosome biogenesis, and DNA replication) has previously been established 
and offers an explanation for the enhanced glutamine anabolism we report.  GS-driven 
glutamine synthesis is the only known reaction for endogenous glutamine production.  
In mammals, nearly 90% of glutamine production originates from endogenous sources 
(Biolo et al., 2005; Kuhn et al., 1999).  While muscle tissue accounts for the majority of 
synthesized glutamine that can be released into the circulating system and taken up by 
other tissues and tumors, many tissues and cell types have the ability to upregulate GS 
and glutamine synthesis upon glutamine shortage (He et al., 2010; Newsholme et al., 
2003).  In cells with Myc amplification, increased biosynthetic processes may increase 
the demand for glutamine to serve as a basis for many anabolic processes.  This is 
supported by a recent report that de novo glutamine synthesis was found to be elevated in 
human glioblastoma (Maher et al., 2012).  Therefore, oncogenic Myc may hijack the 
glutamine synthesis system to ensure glutamine supply for autonomous need or perhaps 
in a symbiotic fashion that benefits tumor tissue heterogeneity and microenvironment, 
especially under the condition of glutamine shortage such as in poorly vascularized 
tumors.   
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While our findings are seemingly paradoxical to Myc’s role in promoting glutaminolysis 
to facilitate energy production via the entry of glutamate into the TCA cycle, it is not 
entirely surprising.  Indeed, recent reports highlighted glucose oxidation as a 
predominant fuel source in patient samples and human orthotopic tumor models which 
show glucose as a means of anaplerosis and accumulation of glutamine in tumors (Maher 
et al., 2012; Marin-Valencia et al., 2012).  Myc may preferentially activate either 
glutaminolysis or glutamine synthesis in a context-dependent manner.  This notion is 
supported by the observations that Myc often does not lead to simultaneous upregulation 
of GLS and GS (Yuneva et al., 2012), and that a mutual suppressive mechanism may 
even exist between GS and GLS in various breast cancer subtypes (Kung et al., 2011).  
In addition, within a single cell, the two reactions may be tightly regulated as they occur 
at different subcellular compartments: glutaminolysis predominantly in mitochondria and 
glutamine synthesis in the cytosol (Svenneby and Torgner, 1987).  The precise 
regulation and biological relevance of glutaminolysis and glutamine synthesis requires 
further study.     
 
We also show that Myc-induced GS expression is mediated by a novel mechanism that 
involves active promoter demethylation.  Although we cannot completely rule out the 
possibility that Myc may activate GS expression via other mechanisms, our data indicate 
that Myc can induce GS expression by directly activating the expression of the DNA 
demethylase TDG.  This is consistent with recent genome-wide analyses that identified 
Myc-binding in the TDG promoter (Perna et al., 2012; Walz et al., 2014).  DNA 
methylation has been regarded as a critical factor in oncogenesis yet its precise role and 
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regulation remain largely elusive.  Promoter hypermethylation leading to repression of 
tumor suppressor genes is a well-recognized tumor-promoting mechanism.  Along this 
direction, TET inactivation or suppression, via genetic alterations or biochemical 
inhibitions by cell metabolites such as 2-hydroxyglutarate (2-HG), has been implicated in 
cancer development.  Nevertheless, global hypomethylation has also been prevalently 
detected and recognized as a cause for cancer, although the regulation of specific genes is 
yet to be illustrated (Das and Singal, 2004; Kulis and Esteller, 2010).  Our current data 
provides a novel example that Myc can induce DNA demethylation and alters cell 
metabolism to promote its oncogenic function.  This is consistent with the evidence that 
active DNA demethylation plays an important role in the development of germ cells and 
pluripotent stem cells (Wu and Zhang, 2014), which share many common signaling 
pathways and metabolic alterations with Myc-driven oncogenesis (Goding et al., 2014).    
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Experimental Procedures 
 
 
Antibodies and reagents 
The following antibodies were used: GS (G2781; 1:2,000 for WB from Sigma-Aldrich; 
BD 610517 1:1,000 for IHC from Becton-Dickinson), tubulin (T4026; 1:5,000 for WB) 
from Sigma-Aldrich; Myc (N-262; 1:750 for WB, N-262X; 10 g per 100 g DNA for 
ChIP) from Santa Cruz Biotechnology; GLS (WH00027441M1; 1:1,000 for WB) from 
Sigma-Aldrich; TDG (ab154192; 1:2,000 for WB) from Abcam.  The shRNAs were 
from Sigma-Aldrich.  Gemcitabine was from Enzo Life Sciences, Inc.  5-azacytidine 
was from Sigma-Aldrich.  U-13C glucose and 15N-NH4Cl were purchased from 
Cambridge Isotopes (CLM-1396).  BPTES (SML0601) and MSO (M5379) were 
purchased from Sigma-Aldrich. 
 
Cell lines and culture 
The dual-regulatable FL5.12 Tet-myrAkt/MycER (AM) clones were established 
previously (Fan et al., 2010).  Cells were maintained in complete medium (RPMI 1640 
medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 
units/ml penicillin, 100 g/ml streptomycin, 20 mM HEPES, pH 7.5, 50 M 2-
mercaptoethanol, and 0.4 ng/ml IL-3).  The Myc-expressing MCF10A cells were 
established by retroviral infection of the pBabe-c-Myc construct and selected in 8 g/ml 
puromycin for 4 days and used as a stable cell pool.  The cells were maintained in 
MCF10A complete medium (DMEM and F-12 medium supplemented with 5% horse 
serum, 100 units/ml penicillin, 100 g/ml streptomycin, 20 ng/ml EGF, 0.5 g/ml 
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hydrocortisone, 0.1 g/ml cholera toxin, and 10 g/ml insulin).  MCF7, Hs578T, and 
HEK293T cells were cultured in complete medium (DMEM with 10% FBS, 100 units/ml 
penicillin, 100 g/ml streptomycin, and 10 g/ml insulin).  MDA-MB-231 and MDA-
MB-468 cells were cultured in complete medium (MEM with 10% FBS, 100 units/ml 
penicillin, 100 g/ml streptomycin, 1 mM sodium pyruvate, 1% MEM NEAA and 1% 
Hyclone vitamin mix).  SKBR3 cells were cultured in complete medium (McCoy’s 5A 
with 10% FBS, 100 units/ml penicillin, 100 g/ml streptomycin).  T47D cells were 
cultured in complete medium (RPMI 1640 medium supplemented with 10% FBS, 100 
units/ml penicillin, 100 g/ml streptomycin, and 0.2 units/ml insulin).  
 
Cell death assay 
Propidium iodide (PI) was added to each sample at 1 g/ml.  Cell viability was 
measured by plasma membrane permeability indicated by PI exclusion using a flow 
cytometer (FACSCalibur, BD Biosciences). 
 
Cell growth assay 
Cell growth rate was measured by crystal violet staining.  Briefly, cells were fixed with 
4% PFA then stained with 0.1% crystal violet.  After washing, crystal violet was 
extracted with 10% acetic acid and absorbance was measured at 590 nm.  Readings for 
subsequent days were normalized to the reading of day zero.  
 
Immunoblotting 
Cell lysates were prepared in RIPA buffer (1% sodium deoxycholate, 0.1% SDS, 1% 
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Triton X-100, 0.01M Tris pH 8.0, 0.14M NaCl).  All primary antibodies were incubated 
overnight at 4 °C.  Horseradish peroxidase (Rockland) or Alexafluor-conjugated goat 
anti-rabbit (IRDye 800 - Rockland) or goat anti-mouse (Alexafluor-680 - Life 
Technologies) antibodies were used as secondary antibodies (1:2,000-1:4,000).  Western 
blots were developed using an ECL detection kit (Thermo Scientific) or an Odyssey 
Imager (LI-COR). 
 
GS expression in mouse tumor models examined by RNA-seq 
Murine lung tumor cells derived from viral-Cre induced LSL-KRasG12D; tp53flox/flox mice, 
generously provided by Tyler Jacks (Winslow et al., 2011), were infected with pBabe-
MycERT2 (Murphy et al., 2008), selected on puromycin and treated for 24 h with 100 nM 
4-OHT or ethanol vehicle.  Purified mRNA was subjected to Illumina sequencing.  
Sequence alignment was performed using TopHat (Kim et al., 2013) and analyzed using 
R (Anders et al., 2013). 
 
Immunohistochemistry 
5 M sections of FFPE archived tumor-bearing pancreata from Pdx1-CRE; LSL-
KRasG12D; Rosa26-LSL-Myc mice (Nathiya Muthalagu and DJ Murphy, unpublished 
results) were de-paraffinized and rehydrated through graded alcohols.  After standard 
antigen retrieval (microwaving in 10mM Sodium Citrate pH6.0), endogenous peroxide 
was quenched in 3% H2O2 and sections were blocked for 1hr in 5% BSA.  Primary 
antibody against GS (BD 610517; (Meabon et al., 2012)) was added at 1:1,000 in 
blocking buffer and incubated o/n at 4 oC.  Bound antibody was detected with biotin-
Bott et al.  Page 20 
 
conjugated anti-mouse IgG, followed by avidin/biotin-HRP binding (Vector Labs), 
stained with stable DAB (Invitrogen) and counterstained with Gil 1 Hematoxylin. 
 
Quantitative RT-PCR 
Total RNA was isolated with RNeasy kit (Qiagen).  Reverse transcription was carried 
out with 2 g of total RNA using the SuperscriptIII First Strand Synthesis system 
(Invitrogen).  The synthesized cDNA was used for real-time quantitative PCR (qPCR) 
with the PerfeCTa SYBR Green Super mix (Quanta Bioscience 95055) on the 
StepOnePlus (Applied Biosystems).  The sequences of primer sets were: hGLUL, 
ACTTCGCAAGCGGCACCA and TTGGCTACACCAGCAGAAAA; mGLUL, 
CGTTTTATCTTGCATCGGGT and CCTCAATGCACTTCAGACCA; hDNMT1, 
GCACAAACTGACCTGCTTCA and GCCTTTTCACCTCCATCAAA; hDNMT3a, 
GACAAGAATGCCACCAAAGC and CGTCTCCGAACCACATGAC; hDNMT3b, 
CCAGCTGAAGCCCATGTT and ATTTGTCTTGAGGCGCTTG; hTET1, 
GCCTGGACTTCTGTGCTCAT and CTCGATGGCCCCAGATTTGA; hTET2, 
CTCGCATGCAAGTCACGTC and ATGTTTGCCAGCCTCGTTCT; hTET3, 
CTGAGAACCCACTCACACCC and TCCATACCGCTCCTCCATGA; mTET3, 
GCCTCAATGATGACCGGACC and AGTGGCCAGATCCTGAAAGC; hTDG, 
TGGACGTTCAAGAGGTGCAA and CCACGCTCTCAATTAGCCCA; mTDG, 
TGATGTAGCAGCGTGGGAGG and CTTGCTCCAGAGAATAGCTGCG; hMBD4, 
ACCATCCCACGAACACAGAT and CCATTTTGCCTGAGGTCCGA; hGAPDH, 
AAGGTCGGAGTCAACGGATTTG and CCATGGGTGGAATCATATTGGAA; 
mACTIN, CTGTCGAGTCGCGTCCA and CATCACACCCTGGTGCCTA.  The 
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relative abundance of specific mRNAs was normalized to human GAPDH or mouse 
ACTIN mRNA as the invariant control. 
 
Measurement of glutamine synthetase activity 
Glutamine synthetase activity was assessed using a previously described method to 
measure -glutamylhydroxamate synthesized from glutamine and hydroxylamine (Deuel 
et al., 1978).  Briefly, the cells were lysed in 50 mM imidazole-HCl, pH 6.8.  After 
removing debris by centrifugation, lysates were incubated with an equal amount of buffer 
containing 50 mM imidazole-HCl (pH 6.8), 50 mM L-glutamine, 25 mM hydroxylamine, 
25 mM sodium arsenate, 2 mM MnCl2, and 0.16 mM ADP, for 30 min at 37℃.  
Reaction was stopped by the addition of a buffer containing 90 mM FeCl3, 1.45% 
trichloroacetic acid, and 1.8 M HCl.  The solution was cleared by centrifugation at 
16,000 x g for 10 min at 4 °C, and -glutamylhydroxamate was measured in the 
supernatant at 560 nm. 
 
Affymetrix oligonucleotide array 
Total cellular RNA was isolated with RNeasy kit.  Subsequent RNA processing 
procedures and Affymetrix Murine Genome Array U74Av2 application were followed 
according to the manufacturer's protocol (Affymetrix, Santa Clara, CA) by the Stony 
Brook University DNA Microarray Facility.  The data sheet for Affymetrix Murine 
Genome Array for the U74Av2 chips can be found at 
http://www.affymetrix.com/products/arrays/specific/mgu74.affx.  Data were analyzed 
using Affymetrix Genechip and GeneSpring software.  The analysis of the data was 
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performed at the Stony Brook University DNA Microarray Center 
(http://www.osa.sunysb.edu/udmf/) with the help of the Bioinformatics Core Facility 
(http://www.osa.sunysb.edu/bioinformatics/index.html).   
 
5-azacytidine treatment 
Cells were treated with 20 M 5-azacytidine (Sigma-Aldrich) every 24 h over a 96 h 
period.  Total RNA was then isolated and analyzed by qRT-PCR. 
 
Bisulfite sequencing 
For the Myc-expressing MCF10A cells, single cell clones and vector control cells were 
established by limited dilution.  Genomic DNA was isolated from each single cell 
clone.  For sequencing, bisulfite-converted DNA was PCR amplified using methyl 
sequencing primers, GTTTTTTTTTAAGTTAATTTTTG (-111~ -90) and 
ATACCCTAATTAACTCCCAAC (+343~+363).  The PCR product was extracted from 
the gel and sequenced using the primer GTTTTTTTTTAAGTTAATTTTTG (-111~ -90) 
or AAAAAACTAAAAACAAAAAAAC (+151~+172).  For MCF10A-MycER and 
FL5.12-AM32 cells, cells were left untreated or treated with 4-OHT (8 h for MCF10A-
MycER and 4 h for FL5.12-AM32).  Cells were collected and the genomic DNA was 
extracted with QIAamp DNA Mini Kit (Qiagen).  The purified genomic DNA was 
subjected to bisulfite treatment with MethylEdge™ Bisulfite Conversion System 
(Promega).  The bisulfite converted DNA was used as template for PCR with primer 
pairs, for MCF10A-MycER cells, 5’ CTCCCTCTCAAACTAACCCCT3’ (-111~-91) and 
5’ GGAGGGTTGAGGGTAGAGGG3’ (+153~+171); and for FL5.12-AM32, 
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5’GGATGGGTGAATAGGTTAGGAGAG3’(+85~+107) and 
5’ CCTCCCCCACTCCCCTTTCTC 3’ (-189~-168).  PCR fragments were purified and 
inserted in to pGEM-T vector (Promega).  After the transformation, white colonies were 
verified by colony PCR assay.  Positive colonies were amplified and plasmids extracted 
for sequencing with T7 primers. 
 
DNA demethylase activity assay 
Nuclear proteins were isolated using the EpiQuikTM Nuclear Extraction Kit (Catalog # 
OP-0002).  DNA demethylase activity measurement and calculation were performed 
according to the manufacturer’s protocols and formulas.  DNA demethylase activity was 
measured using 10 μg of nuclear protein extracts with the EpiQuikTM DNA Demethylase 
Activity/Inhibition Assay Ultra Kit (Catalog # P-3008) (Epigentek, Farmingdale, NY, 
USA). 
 
ChIP assay 
ChIP assays were performed according to standard protocols available at Abcam Inc.  
Protein was cross-linked to DNA with the addition of formaldehyde.  Cells were washed 
two times with phosphate buffer saline (PBS) and then scraped into PBS.  Cells were 
collected after centrifugation and lysed in ChIP lysis buffer (50 mM HEPES-KOH, pH 
7.5, 140 mM NaCl, 1 mM EDTA, pH 8.0, 1% Triton X-100, 0.1% sodium deoxycholate, 
0.1% SDS and protease inhibitors).  Resulting cell lysates were sonicated with 
Ultrasonic Processor Sonicator W-380.  Target proteins were immunoprecipitated 
overnight at 4 °C with protein A conjugated Sepharose beads in the presence of desired 
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antibody.  The beads were washed three times with wash buffer (0.1% SDS, 1% Triton 
X-100, 2 mM EDTA, pH 8.0, 150 mM NaCl, 20 mM Tris·HCl, pH 8.0) and eluted in 
elution buffer (1% SDS, 100 mM NaHCO3).  All DNA samples were purified using 
phenol:chloroform followed by ethanol precipitation in the presence of glycogen before 
qPCR analysis.  Primers used for qPCR analysis of immunoprecipitated DNA were as 
follows: TDG PCR #1: TTACTCACGAAAGCCTGGATC (-909~ -889) and 
CATGGCTGCTGTATTTGTTGG (-746~ -726); TDG PCR #2: 
CTCCCTCACATCTCATTACCTG (-318~ -297) and 
GCTTTTGTCTCCAGTATTTTCGG (-165~ -143). 
 
Luciferase assay 
A 1.2 kb fragment containing the TDG 5’-flanking region was PCR amplified from 
genomic DNA of MCF10A cells.  The PCR product was cloned into the pGL3 vector 
containing the firefly luciferase reporter.  PCR based site-directed mutagenesis was 
performed to ablate the two putative E-boxes individually or simultaneously.  All 
constructs were confirmed by DNA sequencing.  To examine the promoter activity, 
MCF10A cells stably transduced with either vector or Myc were transiently transfected 
with the promoter constructs along with internal control plasmid pCMV-RL using 
Lipofectamine 2000.  Cells were seeded at 5 x 104 cells per well in 24-well plates.  
Transfections were comprised of either wild-type or mutant E-box TDG promoter 
luciferase vectors (1.0 µg) together with pCMV-RL (100 ng).  Twenty-four hours post 
transfection, cells were washed with PBS and lysed in 100 µl passive lysis buffer for 10 
minutes.  Luciferase activity was determined following the manufacturer’s 
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recommended protocol with a SpectraMax M5 Microplate Reader.  The ratios of firefly 
luciferase versus renilla luciferase were used as relative luciferase activities. 
 
Amino acid transport assays 
Amino acid uptake was performed as previously described (Krokowski et al., 2013). 
Briefly, cells were grown in 24-well plates to 70% confluency.  Uptake assays were 
performed after wash out of growth media in EBSS with sodium chloride replaced with 
choline chloride.  Leu uptake was performed at 10 M (4 Ci/ml) for 1 min at 37°C.  
Ethanol extracted radioactivity was normalized over protein content assayed by the 
Lowry method.  The inhibitor of system L-BCH (Sigma-Aldrich) was used at 5mM 
concentration.  Amino acid depletion was performed after washing cells with warm PBS 
and incubation in amino acid free KRB (Sigma-aldrich) supplemented with 10% dialyzed 
FBS (Gibco) and insulin or DMEM without Gln supplemented with 10% dialyzed FBS 
and insulin. 
 
Measurement of extracellular glutamine 
5x105 cells were seeded in 6-cm plate overnight.  Cell culture medium was replaced 
with 2.5 ml fresh medium and cultured for 48 h.  1.5 medium was collected and the 
concentration of glutamine was determined using an automated electrochemical analyzer 
(BioProfile 100 Plus analyzer; NOVA Biomedical, Waltham, MA, USA).   
 
Analysis of metabolites by GC-MS  
For 13C-glucose labeling, protocols have been outlined previously (Faubert et al., 2013).  
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Briefly, cells were cultured in glutamine-free medium for 16 h, then cultured with 12.5 
mM U-13C glucose.  Cells were washed with ice-cold 0.9% saline solution, lysed with 
ice-cold 50% methanol on dry ice, supplemented with the internal standard adonitol, and 
subjected to three rounds of rapid freeze thaw between liquid nitrogen and 37 °C or 
sonication.  Lysate was pelleted by centrifugation at 12,000 x g for 10 min at 4 °C and 
the supernatant was transferred to glass containers for sample concentration and 
derivatization.  Dried samples were re-suspended in 30 μL anhydrous pyridine 
containing methoxyamine (10 mg/ml) and added to GC-MS autoinjector vials containing 
70 μL N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA) 
derivatization reagent.  The samples were incubated at 70 oC for 1 h, following which 
aliquots of 1 L were injected for analysis.  GC-MS data were collected on an Agilent 
5975C series GC/MSD system (Agilent Technologies) operating in election ionization 
mode (70 eV).  Data were corrected for natural abundance.  
 
For 15N-NH4Cl labeling, cells (2 x 10
6) were plated and washed three times with pre-
warmed PBS.  Cells were overlaid with 5 mM 15N-NH4Cl in glutamine free DMEM for 
6 h after which cells were washed with ice-cold 0.9% saline solution, lysed with ice-cold 
50% methanol on dry ice, supplemented with the internal standard adonitol, and 
subjected to three rounds of rapid freeze thaw between liquid nitrogen and 37 °C.  
Lysate was pelleted by centrifugation at 12,000 x g for 10 min at 4 °C and the 
supernatant was transferred to glass containers for sample concentration and 
derivatization.  Supernatants were dried under constant air flow for a minimum 4 h at 42 
°C, then treated with Methoxamine Reagent (Thermo Scientific) overnight at room 
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temperature to prepare oximes of ketoacids before silylation.  Samples were dried under 
constant air flow for a minimum of 2 h, then treated with TRI-SIL (Thermo Scientific) 
for 2 h at 42 °C to derivatize.  GC-MS data was collected on an Agilent 7890B 
GC/5977A MS.  Glutamine was monitored at 258, 259 and 260 m/z.  Data were 
analyzed using Mass Hunter and corrected for natural abundance using ISOCOR.  
Quantified metabolites were normalized relative to protein content or cell number.   
 
Measurement of 15N-labeling pattern of cellular metabolites using LC-MS 
Hs578T and MCF10A cells were plated and cultured in DMEM with dialyzed serum for 
48 h to reach 90% confluency.  Cells were washed three times with pre-warmed PBS 
and overlaid with 5 mM 15N-NH4Cl in glutamine replete media (2 mM) for 16 h after 
which media was aspirated and cells were overlaid with ice-cold 80% methanol.  Plates 
were incubated at -80°C for 15 min, scraped, and transferred to polypropylene tubes.  
Cells were pelleted by centrifugation and supernatant was transferred to fresh tubes.  
Pellets were washed twice with 80% methanol and supernatants collected.  The cell 
extracts were dried under nitrogen flowing, and re-dissolved in 500 μL HPLC-grade 
water, and analyzed via reverse-phase ion-pairing chromatography coupled to an 
Exactive orbitrap mass spectrometer (ThermoFisher Scientific, San Jose, CA).  The 
mass spectrometer was operated in negative ion mode with a scan rate of 1 Hz and 
resolving power of 100,000, scanning range being m/z 75-1000.  The LC method has 
been described previously (Lu et al., 2010), using a Synergy Hydro-RP column (100 mm 
× 2 mm, 2.5 μm particle size, Phenomenex, Torrance, CA) with a flow rate of 200 
μL/min.  The LC gradient was 0 min, 0% B; 2.5 min, 0% B; 5 min, 20% B; 7.5 min, 
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20% B; 13 min, 55% B; 15.5 min, 95% B; 18.5 min, 95% B; 19 min, 0% B; 25 min, 0% 
B.  Solvent A is 97:3 water:methanol with 10 mM tributylamine and 15 mM acetic acid; 
solvent B is methanol.  Other LC parameters were autosampler temperature 5°C, 
injection volume 10 μL, and column temperature 25 °C.  Data analyses were performed 
using MAVEN software (Melamud et al., 2010).  The metabolites, both unlabeled and 
the 15N-labeled forms, were detected using the accurate mass with an 8 ppm m/z window.  
Labeling percentages were calculated from signal intensity using Excel. 
 
Xenograft experiments 
Female athymic nude mice, 6 to 8 weeks old, were obtained from Charles River 
Laboratories.  Mice were housed and monitored at the Division of Laboratory Animal 
Resources at Stony Brook University.  All experimental procedures and protocols were 
approved by the Stony Brook University institutional animal care and use committee 
(IACUC).  Tumors were established by resuspending 1 x 106 MDA-MB-468 cells 
carrying a Tet-inducible shRNA for GS in 50 µl Matrigel and injecting in the mid-flanks 
of mice using a 26-gauge needle.  Experimental mice received 5% sucrose water with 
doxycycline hyclate (1 mg/ml) changed every 48 h to induce shRNA.  For each tumor, 
the tumor length (l) and the width (w) was measured every 3-4 days with an electronic 
caliper.  Tumor volume (v) was calculated using the formula v = (l x w) x (l + w/2) x 
0.56 and plotted in mm3. 
 
Statistical analyses 
The longitudinal data analyses were performed to assess the growth curves under 
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different treatments.  The ANOVA procedures were used to evaluate differences among 
multiple groups with the Dunnett or Newman-Keuls test.  The independent two-sample 
and one sample t-tests were used to make comparisons between two groups and to 
evaluate whether fold changes are different from one, respectively.  The analyses were 
mainly carried out using PROC MIXED, PROC FREQ, PROC MEANS and PROC 
TTEST in the SAS 9.4 (SAS institute, Cary, NC).  Some initial analyses were also 
carried out with GraphPad Prism 5 for Windows (GraphPad Software Inc, San Diego, 
CA).  Different levels of statistical significance are indicated as: * for p<0.05, ** for 
p<0.01, *** for p<0.001, and **** for p<0.0001. 
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Figure Legends 
 
Figure 1.  Myc upregulates GS expression.  (A) FL5.12 parental cells and the AM 
clones (AM10 and AM32) were cultured in the control medium, with Dox to activate 
Akt, or 4-OHT to activate Myc, or both, for 36 h.  Mouse cDNA microarray analysis 
was performed.  The fold change of GS expression is shown.  (B-D) FL5.12 parental 
and the AM clones were cultured without or with 4-OHT to activate Myc for 36 h.  (B) 
GS transcript level was analyzed by qRT-PCR, and normalized to that of cells without 4-
OHT treatment.  Data shown are the mean of a representative experiment performed in 
triplicates.  ***p<0.001.  (C) Cell lysates were collected and analyzed by 
immunoblotting for indicated proteins.  (D) GS activity was determined using the total 
cell lysates.  Data shown are the mean plus SEM of at least 5 independent experiments.  
*p<0.05.  (E) Hs578T cells overexpressing GS were treated with 100 µM MSO for 24 h 
then tested for GS activity.  Data shown are mean of 2 samples.  (F) HEK293T cells 
with two independent shRNAs against GS were tested for GS activity.  Data shown are 
mean plus SD of 3 individual samples.  (G) Pancreata from 2-month old Pdx1-Cre; 
LSL-KRasG12D (n = 4) and age-matched Pdx1-Cre; LSL-KRasG12D; R26-LSL-MYC 
(n = 4) mice were stained for GS by IHC.  I: Islets; N: normal tissue; T: tumors.  Note 
that tumors in all 4 KRasG12D mice are negative, whereas tumors in all 4 
KRasG12D/Myc mice are positive for GS.  Shown are representative micrographs of 
tumors from one mouse of each group.  (H) Murine lung tumor cells derived from viral-
Cre induced LSL-KRasG12D; p53fl/fl mice were infected with pBabe-MycERT2 and treated 
for 24 h with ethanol vehicle or 100 nM 4-OHT.  Purified mRNA was subjected to 
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Illumina sequencing.  Sequence alignment was performed using TopHat and analyzed 
using R.  GS mRNA levels are expressed as number of sequencing reads.  Shown is the 
mean value plus SD (n=4).  **** p<0.0001.  (I-L) MCF10A cells were stably 
transfected with vector or pBabe-c-Myc.  (I) Cell lysates were probed for indicated 
proteins by immunoblotting.  (J) Cell growth was measured by crystal violet staining 
and normalized to that of cells on day zero.  Data shown are the mean plus SD of a 
representative experiment of three independent experiments performed in triplicates.  
(K) Total RNA was extracted and GS transcript level was analyzed by qRT-PCR, and 
normalized to that of vector control cells.  Data shown are the mean plus SEM from 3 
independent experiments performed in duplicates.  *p<0.05.  (L) GS activity was 
measured.  Data shown are the mean plus SEM of 3 independent experiments.  
*p<0.05.  (M) Differential expression levels of GS in Myc-high and Myc-low groups in 
T-cell lymphoma (ipbal, PMID: 19965671).  Shown are box plots of expression levels of 
GS.  The Myc high and Myc low groups were defined by Myc expression levels above 
or below the median level.  Two-tailed t-tests were performed to test the significance of 
the differences in gene expression.  **p<0.01.  (N) Indicated cell lines were stably 
infected with control shRNA (shNTC) or Myc shRNA (shMyc).  Indicated proteins were 
probed by immunoblotting.   
 
Figure 2.  Myc upregulates GS expression via TDG-mediated demethylation of GS 
promoter.  (A) Total lysates of indicated breast cancer cell lines were probed for GS 
expression.  (B) Schematic representation of the CpG distribution in the 5′-regulatory 
region of the GLUL gene from the CpG Island Searcher (http://www.cpgislands.com).  
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The CpG sites are represented by vertical tick marks, and the beginning of exon 1 is 
depicted as “+1”.  (C) MCF10A cells and Hs578T cells were treated with 20 M 5-
azacytidine (5-Aza) for indicated times.  Total RNA was extracted and GS transcript 
levels were analyzed via qRT-PCR, and normalized to that of untreated cells.  Data 
shown are the mean plus SEM of a representative experiment performed in triplicates. 
*p<0.05; ****p<0.0001.  (D) Single cell clones of vector control and Myc-expressing 
MCF10A cells were established by limited dilution.  The GS promoter was PCR 
amplified in 5 clones of each cell type, and analyzed by bisulfate sequencing.  The 
schematics of the sequencing results and the human GS promoter with the numbered 
CpGs are shown.  Open and filled circles indicate unmethylated and methylated 
cytosines, respectively.  (E) TDG transcript level was analyzed by qRT-PCR in vector 
control or Myc-expressing MCF10A cells, and normalized to the level in the vector 
control.  Data shown are the mean plus SEM of 5 independent experiments performed in 
triplicates.  *p<0.05.  (F) DNA demethylase activity was determined using the 
EpiQuikTM DNA Demethylase Activity/Inhibition Assay Ultra Kit in vector control or 
Myc-expressing MCF10A cells, and normalized to that in vector control.  Data shown 
are the mean plus SEM of 4 independent experiments.  *p<0.05.  (G) Vector control 
and Myc-expressing MCF10A cells were treated with vehicle control or gemcitabine at 
indicated concentrations for 24 h.  GS expression was detected by immunoblotting.  
(H) The level of Myc binding to the TDG promoter in vector and Myc-expressing 
MCF10A cells was analyzed by ChIP assay using the Myc antibody followed by PCR of 
two specific regions within the promoter (PCR#1 and PCR#2).  Fold enhancement 
represents the abundance of enriched DNA fragments over an IgG control.  Data 
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represent mean plus SEM from 3 independent experiments performed in duplicates.  ** 
p<0.01.  (I) Vector control or Myc-expressing MCF10A cells were transfected with the 
luciferase reporters driven by the pGL3 control vector, the wild-type TDG promoter, or 
the TDG promoter mutants with the two E-boxes mutated individually or simultaneously, 
together with a renilla luciferase construct.  Twenty-four hours post transfection, cells 
were lysed and luminescence was quantified.  Luciferase activity was standardized 
based on renilla luciferase activity and normalized to that of the pGL3-transfected cells.  
Data shown are the mean plus SD of a representative experiment performed in triplicates.  
**p<0.01; ***p<0.001.  (J) FL5.12-AM32 cells were cultured in the absence or 
presence of 4-OHT for indicated time periods.  Expression levels of GS and TDG were 
analyzed by qRT-PCR, and normalized to that of cells cultured in the absence of 4-OHT.  
Data shown are the mean plus SEM from 2 independent experiments performed in 
triplicates or duplicates.  *p<0.05, **p<0.01, ****p<0.0001.  (K) Vector control or 
Myc-expressing MCF10A cells were stably infected with lentiviral shRNA control 
(shNTC) or hairpins targeting TDG (shTDG).  TDG transcript level was analyzed by 
qRT-PCR, and normalized to that in vector control cells.  Data shown are the mean plus 
SEM of an experiment performed in triplicates.  *p<0.05; **p<0.01. 
 
Figure 3. GS leads to increased cataplerotic flux towards glutamine synthesis and 
promotes nucleotide synthesis.  (A) Hs578T cells were stably transfected with vector 
control or GS.  Indicated proteins were probed by immunoblotting.  (B) Hs578T cells 
were labeled with 15N-NH4Cl for 6 h in glutamine deficient media and nitrogen 
incorporation into glutamine was determined by GC-MS.  The total pool of glutamine 
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was normalized for stable isotope natural abundances.  Fractional 15N glutamine is 
indicated as black bars and 14N as white bars.  *p<0.05; **p<0.01.  (C-F) Metabolic 
tracing analysis of the vector control or GS-expressing Hs578T cells.  Cells were 
cultured in glutamine-free medium for 16 h before labeling with 12.5 mM 13C-glucose for 
6 h in glutamine-free medium.  Relative abundance of 12C and 13C in each metabolite 
pool was measured by GC-MS, and is expressed relative to the internal standard and 
protein content in each sample normalized to the value of 12C fraction in vector control 
cells (C: glutamine, D: glutamate, E: -KG, F: other indicated metabolites).  All data 
represent total labeling, i.e. all isotopologues.  Data represent mean plus SD from 3 (in 
some cases 2) samples.  n.s. non-significant; *p<0.05, **p<0.01.  (G) Hs578T cells 
were labeled for 16 h with 15N-NH4Cl in glutamine replete (2 mM) medium and 
subjected to LC-MS.  Percent of each 15N labeled molecule is shown.  All data 
represent total labeling, i.e. all isotopologues.  Data shown are mean plus SD from 3 
individual samples.  n.s. non-significant; **p<0.01; ***p<0.001; ****p<0.0001.  (H) 
Vector control and Myc-expressing MCF10A cells were labeled with 15N-NH4Cl for 6 h 
in glutamine deficient media and nitrogen incorporation into glutamine was determined 
by GC-MS.  The total pool of glutamine was normalized for stable isotope natural 
abundances.  Fractional 15N glutamine is indicated as black bars and 14N as white bars.  
*p<0.05.  (I and J) Myc-expressing MCF10A cells were stably infected with lentiviral 
control (shNTC) or GS (shGS) short hairpin.  (I) Cell lysates were analyzed by 
immunoblotting to show successful GS silencing.  (J) Parental, Myc-expressing, and 
Myc-expressing with GS silencing MCF10A cells were labeled for 16 h with 15N-NH4Cl 
in glutamine replete (2 mM) media and subjected to LC-MS.  Percent of each 15N 
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labeled molecule is shown.  All data represent total labeling, i.e. all isotopologues.  
Data shown are mean plus SD from a representative of three independent experiments 
performed in triplicate.  n.s. non-significant; *p<0.05; **p<0.01; ***p<0.001; 
****p<0.0001.   
 
Figure 4. GS promotes amino acid uptake and tumor cell survival/growth.  (A) 
Hs578T cells were tested for leucine uptake at basal conditions, under amino acid 
withdrawal (KRB), and under glutamine deprivation alone for 5 h.  System L-dependent 
uptake of leucine was assayed in EBSS without sodium and confirmed by the use of the 
System L inhibitor BCH.  The amount of Leu uptake was normalized to that of the 
vector control cells cultured in DMEM.  Data shown are mean plus SD of 3 samples 
from a representative experiment of three independent experiments.  **p<0.01.  (B) 
Extracellular glutamine levels in media from HS578T cells was measured with a NOVA 
Bioanalyzer 100 Plus.  Concentration was normalized to protein concentration and 
displayed as a fold change from vector cells.  Data shown are mean plus SD of two 
experiments performed in triplicates.  *p<0.05.  (C) Vector control and GS-expressing 
Hs578T cells were cultured in glutamine-free medium for the indicated periods of time.  
Cell viability was determined by PI exclusion.  Data shown are the mean plus SD of 
three independent experiments.  ****p<0.0001.  (D) The cells in (C) were stained with 
the cell permeable DNA dye Hoechst33342, and observed with a fluorescence 
microscope at day 5.  Note more cell death in vector control cells upon glutamine 
deprivation indicated by cell detachment and condensed nuclei.  (E) Myc-expressing 
MCF10A cells with shNTC or shGS were cultured in complete medium.  Cell growth 
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was measured by crystal violet staining and normalized to that of cells on day zero.  
Data shown are the mean plus SD of a representative experiment of three independent 
experiments performed in triplicates.  ****p<0.0001.  (F) Myc-expressing MCF10A 
cells with shNTC or shGS were cultured in complete or glutamine-free media for 
indicated days.  Cell viability was measured by PI exclusion.  Data shown are the mean 
plus SD of a representative experiment performed in triplicates.  *p<0.05, **p<0.01.  
(G and H) Indicated cell lines were stably infected with two independent shRNAs against 
GS.  Cell were analyzed by immunoblotting with indicated antibodies (G).  Cells were 
cultured and growth rate was measured by crystal violet staining and normalized to the 
value at day zero.  Data shown are mean plus SD of three individual samples (H).  (I) 
MDA-MB-231 cells infected with two individual shGS hairpins were measured for 
spontaneous cell death by PI exclusion.  Data shown are the mean plus SD of three 
individual samples.  (J) Myc-expressing MCF10A cells were cultured in complete 
medium or glutamine-free medium, in the absence or presence of the GS inhibitor 
methionine sulfoximine (MSO) at indicated concentrations.  Cell viability was measured 
48 h later by PI exclusion.  Data shown are the mean plus SD of a representative 
experiment performed in triplicates.  ***p<0.001, ****p<0.0001.  (K and L) MCF10A 
cells were cultured in complete or glutamine-free medium, in the absence or presence of 
the GS inhibitor MSO (D) or the GLS inhibitor BPTES (E).  Cell viability was 
measured 48 h later by PI exclusion.  Data shown are mean plus SD of a representative 
experiment of two independent experiments performed in triplicates.  *p<0.05, 
****p<0.0001.   
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Figure 5. GS promotes tumorigenesis in vivo.  MDA-MB-468 cells were stably 
infected with a Tet-inducible shRNA for GS.  (A) Cells were cultured with doxycycline 
for indicated days.  Successful silencing of GS was detected by immunoblotting.  (B) 
Cells were treated with or without doxycycline for indicated periods of time.  Cell 
growth was measured by crystal violet staining and normalized to the value at day zero.  
Data shown are the mean plus SD of a representative experiment of three independent 
experiments performed in triplicates. ****p<0.0001.  (C) Cells were injected 
subcutaneously into both flanks of athymic nude mice.  Mice were fed with 5% sucrose 
water without (n = 8) or with (n = 10) doxycycline hyclate (1 mg/ml).  Tumor growth 
was measured by caliper measurement.  Shown is the average tumor size plus SEM. 
****p<0.0001.  Images of tumors are shown in the insert.   
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Supplemental Figure Legends 
 
Figure S1.  Related to Figure 2.  (A) DNMT1, DNMT3A, DNMT3B, TET1, TET2, 
TET3, as well as MBD4 transcript levels were analyzed by qRT-PCR in vector control or 
Myc-expressing MCF10A cells, and normalized to the level in the vector control.  Data 
shown are the mean ± SEM of 5 independent experiments performed in duplicates or 
triplicates.  (B) FL5.12-AM32 clone was cultured without or with 4-OHT to activate Myc 
for 24 h.  Cells were treated with vehicle control or gemcitabine at indicated 
concentrations for 24 h.  GS expression was detected by immunoblotting.  (C and D) 
MCF10A cells were stably infected with the retroviral MycER fusion construct and 
induced with 4-OHT for 8 h.  (C) Cell lysates were analyzed by immunobloting with 
indicated antibodies.  (D and E) Bisulfite sequencing in MCF10A-MycER cells (D) and 
FL5.12-AM32 (E) cells.  5 representative sequencing results are shown for each 
condition.  Open and filed circles indicate unmethylated or methylated cytosine of CpG 
site, respectively.  
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